Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Amirhossein, Masroor,; Nienke, Streefkerk,; Grotel, Martine, Van; James I, Geller,; Marc, Ansari,; Eric, Bouffet,; Archie, Bleyer,; Brice, Fresneau,; Michael, Sullivan,; Kristin, Knight,; Per, Kogner,; Rudolf, Maibach,; Allison F, O'neill,; Vassilios, Papadakis,; Kaukab M, Rajput,; Penelope R, Brock,; Gareth J, Veal,; Alexander E, Hoetink,; Alwin D R, Huitema,; Den Heuvel-Eibrink, Marry M, Van

doi:10.1080/10717544.2026.2665892

Public

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Published in Drug delivery • Dec 31, 2026

Authors:

Masroor, Amirhossein

Streefkerk, Nienke

Van Grotel, Martine

Abstract

Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, impl...

Subject

Childhood cancer

cisplatin

hearing loss

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!